


Brigatinib

Printed from <https://www.cancerquest.org/node/6391> on 02/24/2026



Brand name: Alunbrig

IUPAC: 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine

FDA approval: Yes

[Manufacturer Link](#)

Usage:

Brigatinib is an oral prescription used in the treatment of non-small cell lung cancer. It is often combined with other types of cancer therapy, which produces quality results.¹

¹ Patient Information. (n.d.). Retrieved July 19, 2017, from <https://www.alunbrig.com/>

Mechanism:

Brigatinib is a small molecule targeted cancer therapy used in the treatment of non-small cell lung cancer. Brigatinib has exhibited activity as a strong inhibitor of anaplastic lymphoma kinase (ALK) (cancerous cell proteins) and epidermal growth factor receptor (EGFR), which in turn leads to decrease in cancerous cells and overall apoptosis.¹

¹ Health Care Professionals Information. (n.d.). Retrieved July 19, 2017, from https://www.alunbrig.com/hcp?utm_source=google&utm_medium=cpc&utm_term=brigatinib%2Bmechanism%2Bof%2Baction&utm_campaign=GS%2B-%2BNA%2B-%2BBr%2B-%2BGeneric%2B-%2BHCP_GS%2B-%2BInformation_EX

Side effects:

The most serious side effects of brigatinib include: swelling of the lungs (if extremely severe seek medical attention), high blood pressure, slow heart rate, vision problems and tenderness/weakness. However, the most common side effects include: nausea, diarrhea, stomach problems and headache.¹

Contraindications:

Patients with prior lung or breathing problems should alert their physician before starting a Brigatinib prescription. Women who are pregnant or are looking to become pregnant should be especially careful in taking Brigatinib.[1](#)